ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3004

Autoantibody-Mediated Raynaud’s Phenomenon: Animal Model and Human Disease

Dana P. Ascherman1,2, Yunjuan Zang3, Laisel Martinez4, Judith Pignac-Kobinger5, Irina Fernandez3 and Eric L. Greidinger3,4, 1Medicine/Rheumatology, University of Miami, Miami, FL, 2Rheumatology, Miami VAMC, Miami, FL, 3Rheumatology, University of Miami, Miami, FL, 4Miami VAMC, Miami, FL, 5University of Miami, Miami, FL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, autoantibodies and pathogenesis, Raynaud's phenomenon

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Raynaud’s Phenomenon (RP) is frequently seen in autoimmune conditions, but an autoimmune basis for RP has not been established.

Methods: Sera derived from anti-RNP+ individuals were screened for antibodies associated with RP by immunoprecipitation, western blot, and ELISA.  Autoantigen targets were then identified by mass spectrometry.  Biological effects of antigen-specific monoclonal antibodies as well as human and murine antisera were assessed in in vitro endothelial cell culture and in vivo adoptive transfer experiments involving various wild type and knockout mice.

Results: Immunoprecipitation and mass spectrometric sequencing identified cytokeratin 10 (K10) as a putative antigen linked to RP in anti-RNP+ sera.  Subsequent ELISA-based screening of 123 anti-RNP+ patients demonstrated that antibodies to K10 were strongly linked to the presence of RP (present in 92% of RP patients; Odds Ratio of RP in anti-K10+ patients = 4.6 (95% confidence interval 1.6-13.4).  In vitro endothelial expression of K10 was confirmed at the mRNA and protein level by rtPCR and western blot, respectively.  Fluorescence microscopy further demonstrated that anti-K10 antibodies bound to the surface of K10-expressing endothelial cells, with corresponding induction of endothelial cell apoptosis not observed with control antibodies.  Endothelial cell K10 expression (but not other cytokeratins) was found to be dramatically upregulated by cold exposure in vitro.  Consistent with these observations, in vivo passive transfer of anti-K10+ antisera or anti-K10 monoclonal antibodies to wild type recipient mice induced a high rate of ischemia and damage of thermoregulatory tissues (ears and tail) that was exacerbated by preconditioning with cold exposure.  These effects were not observed in K10 knockout mice, which were resistant to tissue ischemia induced by either anti-K10 antisera or mAb.

Conclusion: Anti-K10 antibodies induce endothelial apoptosis, mediate a murine model of RP via their recognition of the K10 antigen, and are strongly linked with clinically evident RP in human anti-RNP autoimmunity.  These findings suggest that RP may be driven by anti-K10 or other endothelial apoptosis-inducing antibodies, establishing the foundation for development of novel diagnostic and treatment modalities in this frequent complication of systemic autoimmune disease.


Disclosure:

D. P. Ascherman,
None;

Y. Zang,
None;

L. Martinez,
None;

J. Pignac-Kobinger,
None;

I. Fernandez,
None;

E. L. Greidinger,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoantibody-mediated-raynauds-phenomenon-animal-model-and-human-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology